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Purpose: To investigate the association between genetic variation at the matrix metalloproteinase-9 (MMP9) locus and
primary angle closure glaucoma (PACG) in an Australian Caucasian population.
Methods: A total of 107 Australian patients with PACG and 288 age and sex-matched controls were included in the
current study. Tag single nucleotide polymorphisms (SNPs) were selected and genotyped to cover the majority of common
variation within MMP9. Allele, genotype and haplotype association analyses were conducted using PLINK.
Results: Two SNPs from MMP9, rs3918249 and rs17576 were significantly associated under the allelic model with p
values of 0.006 for both SNPs. In addition, haplotype analysis revealed a protective haplotype TACGG to be significantly
more frequent in controls (69%) than in PACG cases (59%), with p=0.006.
Conclusions: This study demonstrates an association between MMP9 SNPs rs3918249 and rs17576 and PACG in the
Australian population, suggesting MMP9 may be involved in the pathogenesis of this blinding disease. Further replication
will be helpful in confirming this finding before future clinical translation.
Glaucoma  is  the  second  leading  cause  of  blindness
worldwide after cataract. It is estimated that 79.6 million
people will be affected by 2020, with 11.2 million patients
affected with bilateral blindness [1]. Primary angle closure
glaucoma  (PACG)  has  high  visual  morbidity  rates  and
accounts for blindness in about half of all blind glaucoma
patients [2].
PACG  patients  have  in  common  similar  anatomic
features such as shallow anterior chamber [3], increased lens
thickness, anterior position of the lens [4], narrow anterior
chamber  angles,  short  axial  length  [5],  and  hyperopic
refractive error [6]. Wang et al. [7], found that first degree
relatives of PACG patients are at 6–9 fold increased risk of
developing PACG. The genes responsible for PACG are still
unknown.
Recently, the matrix metalloproteinase-9 (MMP9) gene
was investigated for association with PACG. MMP9 is one of
tightly regulated family of zinc dependent enzyme, and is
important  in  remodelling  of  extra-cellular  matrix  (ECM)
during  homeostasis  and  remodelling  [8].  A  single  study
identified  an  association  between  a  single  nucleotide
polymorphism  (SNP)  rs17576  in  MMP9  and  PACG  in
Taiwanese patients [9]. A subsequent study on Singaporean
patients did not replicate this association [10], and Cong et al.
[11] also failed to find an association between rs17576 and
PACG  in  a  Southern  Chinese  population.  However,  they
Correspondence to: Jamie E. Craig, Ophthalmology Department,
Flinders University, Flinders Drive, Bedford Park, South Australia,
Australia 5042; Phone: +61 8 8204 6985; FAX: +61 8 8277 0899;
email: jamie.craig@flinders.edu.au
reported an association between SNP rs2250889 in MMP9
and PACG.
In the current study, we aimed to assess tag SNPs in
MMP9  for  association  with  PACG  in  the  Australian
Caucasian population.
METHODS
Participants were recruited from Ophthalmology clinics in
Australia through the Australian and New Zealand Registry
of Advanced Glaucoma (ANZRAG). Approval was obtained
from the human research ethics committee of the Southern
Adelaide Health Service and Flinders University, and was
conducted in accordance with the Declaration of Helsinki and
its  subsequent  revisions.  Written  informed  consent  was
obtained from each individual. All participants share the same
ethnicity (Caucasian).
A total of 107 participants with PACG were recruited.
Every  participant  received  a  complete  eye  examination
including  slit  lamp  examination  of  the  anterior  chamber,
gonioscopy,  central  corneal  thickness,  visual  acuity,
measurement  of  intraocular  pressure,  fundus  examination
with special attention to optic disc parameters, and visual field
assessment.  The  diagnosis  of  PACG  was  based  on  the
presence  of  glaucomatous  optic  neuropathy  with  cup:disc
ratio ≥0.7, peripheral visual loss, presence of at least 180
degrees of closed angle in which the trabecular meshwork is
not  visible  on  gonioscopy.  Patients  with  secondary  angle
closure glaucoma due to uveitis, trauma or lens subluxation
were excluded.
The control group, comprising 288 individuals from the
Australian  population,  was  recruited  from  healthy  age
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1420matched volunteers based in Adelaide, Australia. Controls
were all examined and required to have intraocular pressure
less than 21 mmHg, normal optic nerve heads with cup:disc
ratio of <0.5, normal visual fields and no family history of
glaucoma.
Genomic DNA was extracted from 8 ml of venous blood
using the QiaAmp Blood Maxi Kit (Qiagen, Valencia, CA).
Tag  SNPs  were  selected  using  the  tagger  program
implemented  in  Haploview  4.2,  to  cover  the  majority  of
known genetic variation in and around MMP9 in HapMap
using  CEU:CEPH  (Utah  residents  with  ancestry  from
northern and western Europe). Tag SNPS were chosen using
pairwise tagging, to have an r2>0.8 with SNPs displaying a
minor  allele  frequency  of  10%  in  this  population.  SNPs
previously reported to be associated with PACG were force
included in the selection of tags. These chosen tag SNPs were:
rs3918249  (C/T),  rs17576  (G/A),  rs3918254  (T/C),
rs3787268 (A/G), rs2274756 (A/G). A Bonferroni corrected
p  value  of  0.05/5=0.01  was  considered  statistically
significant.
Genotyping was conducted at the Australian Genome
Research  Facility  using  the  iPLEX  Gold  chemistry
(Sequenom  Inc.,  San  Diego,  CA)  on  an  Autoflex  mass
spectrometer  (Sequenom  Inc.)  at  the  Australia  Genome
Research Facility, Brisbane. All analyses were conducted in
PLINK [12]. SNPs were assessed for compliance with Hardy–
Weinberg equilibrium using the χ2 test. Genetic association
was assessed under allelic, dominant and recessive models.
Where  fewer  than  5  counts  for  a  given  genotype  were
observed, Fisher’s exact test was used, otherwise a χ2 test was
used.  Haplotypes  across  the  single  observed  linkage
disequilibrium block, as visualized in Haploview using the
“confidence  interval”  block  definition  [13],  were  also
analyzed for association using PLINK. Multivariate analysis
was conducted using logistic regression in PLINK.
RESULTS
Three hundred-ninety five Australian participants, consisting
of 107 PACG cases with a mean age of 76±8.2 (females 67%
and males 33%), and 288 healthy controls with mean age
69±11.2 (females 53% and males 47%) were genotyped. A
total of five SNPs were genotyped at the MMP9 locus, with
the physical location presented in Figure 1. All five SNPs
conformed to Hardy–Weinberg equilibrium (p>0.05).
Two  MMP9  SNPs,  rs3918249  and  rs17576,  were
significantly associated under an allelic model with p values
of 0.006 for both SNPs. SNP rs2274756 showed nominal
significance  (p=0.017)  that  did  not  survive  correction  for
multiple testing (Table 1). The C/C genotype of rs3918249
and the G/G of rs17576 were observed more frequently in
PACG  patients  than  in  controls  (Table  2).  Both  were
associated with marginal significance under dominant and
recessive  models.  Multivariate  analyses  were  conducted
controlling  for  age  and  gender,  the  two  SNPs  remained
significantly associated with PACG (p=0.01 for both SNPs).
Analysis of the linkage disequilibrium structure between
the five tag SNPs showed one haplotype block (Figure 2).
Haplotype analysis revealed three common haplotypes in this
population.  The  frequency  of  TACGG  was  significantly
higher in controls (69%) than in PACG cases (59%), p=0.006,
and remained significant after Bonferroni correction for the
Figure 1. MMP9 gene schematic representation, indicating tag SNP location. Exons are indicated by boxes and joined by introns indicated by
solid lines. Figure adapted from the HapMap website.
TABLE 1. ASSOCIATION OF MMP9 TAG SNPS WITH PACG UNDER AN ALLELIC MODEL. POSITION ON CHROMOSOME 20 IS GIVEN IN BASE PAIRS
ALONG WITH FREQUENCY OF ALLELE 1 IN CASES AND CONTROLS.
SNP Position (bp) Allele 1/2 Case Control p-value OR (95% CI)
rs3918249 Chr20:44071543 C/T 0.411 0.305 0.006 1.5 (1.1–2.2)
rs17576 Chr20:44073632 G/A 0.408 0.304 0.006 1.5 (1.1–2.2)
rs3918254 Chr20:44073798 T/C 0.004 0.001 0.469 2.6 (0.1–43)
rs3787268 Chr20:44075138 A/G 0.231 0.192 0.232 1.2 (0.8–1.8)
rs2274756 Chr20:44076518 A/G 0.174 0.111 0.017 1.7 (1.1–2.6)
        A p<0.01 in bold values considered to be statistically significant. bp=base pair, OR=odds ratio, 95% CI=95% confidence interval.
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1421three haplotypes observed (p=0.018). The CGCGA haplotype
was more frequent in PACG cases than controls (17% versus
11% respectively, p=0.035), but did not remain significant
following  multiple  testing  correction  (corrected  p=0.105)
(Table 3).
Figure 2. The haplotype block structure of the tag SNPs of MMP9.
The number in the box represents the r2 value. Values in light blue
boxes do not reach statistical significance.
DISCUSSION
MMP9 is located on chromosome 20q11.2-q13.1 and contains
13  exons.  MMP9  protein  plays  an  important  role  in
extracellular  matrix  remodelling  by  cleaving  denatured
collagen and type IV collagen in the basement membrane.
Regulation  of  MMP9  occurs  at  the  transcriptional  level,
secondary  to  pro-inflammatory  cytokines  [14],  while  the
activation  and  inhibition  of  the  secreted  pro-enzyme
(ProMMP-9),  controls  the  post-transcriptional  regulation
[15].
SNP rs17576 is located in exon 6 of MMP9, where the
mutation leads to the substitution of positively charged amino-
acid (arginine) by an uncharged amino acid (glutamine) at
position  279  [16].  This  non-synonymous  substitution  is
situated  in  the  coding  sequence  of  a  highly  conserved
gelatinase-specific fibronectin type II domain (FN2) [17]. The
FN2 is one of three types of the internal repeats that combine
to form larger domains within fibronectin (a plasma protein
that binds various cell surface compounds such as collagen,
fibrin, heparin, DNA and actin). This domain in MMP9 is
responsible  for  the  collagen  affinity  of  MMP9  [18].  The
precise impact of this polymorphism on protein function is
currently unknown, but it has been suggested that it could lead
to partial loss of function in ECM remodelling which occurs
during eye growth and development [9].
Our study found a significant association of two SNPs in
MMP9 with PACG in the Australian Caucasian population;
rs17576 (G/A; p=0.006) and rs3918249 (C/T; p=0.006), these
SNPs remained statistically significant independent of age
and sex. These two SNPs are in strong linkage disequilibrium
(r2=0.98).  The  minor  allele  of  each  SNP  (G  and  C,
respectively) is associated with PACG under the allelic and
dominant  models.  These  risk  alleles  are  split  across  two
common haplotypes, only one of which is associated with
PACG. The most significantly associated haplotype contains
the common allele at both SNPs and appears to be protective
TABLE 2. GENOTYPE FREQUENCIES OF MMP9 SNPS, AND ASSOCIATION UNDER DOMINANT AND RECESSIVE MODELS.
SNP Genotype Cases n (%) Controls n (%) p-value dominant p-value recessive
rs3918249 CC 19 (17%) 27 (10%) 0.02 0.04
  CT 49 (46%) 109 (41%)    
  TT 38 (36%) 131 (49%)    
rs17576 GG 18 (17%) 27 (10%) 0.02 0.05
  GA 49 (47%) 109 (41%)    
  AA 37 (35%) 132 (49%)    
rs3918254* TT 0 0 0.47 1
  TC 1 (0.9%) 1 (0.3%)    
  CC 105 (99%) 282 (99%)    
rs3787268* AA 7 (6%) 9 (3%) 0.41 0.16
  AG 35 (33%) 85 (32%)    
  GG 64 (60%) 174 (65%)    
rs2274756 AA 4 (4%) 4 (1%) 0.04 0.23
  AG 29 (27%) 51 (19%)    
  GG 73 (69%) 213 (79%)    
               *indicates Fisher’s exact test was used.
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1422with a haplotype frequency of 69% in controls and only 59%
in cases, p=0.006.
Previous studies of the association of SNPs in MMP9
with PACG in different populations have been reported. Wang
et al. [9], found an association between rs17576 and acute
PACG in Taiwanese populations. They postulated that the
gene  activity  may  have  been  down  regulated  in  PACG
patients,  leading  to  reduction  of  MMP9  activity  in  ECM
remodelling during ocular development and thus shorter axial
length. However, other studies on Singaporean and Southern
Chinese patients failed to replicate this finding [10,11]. Cong
et  al.  [11],  also  identified  an  association  of  MMP9  SNP
rs2550889 with PACG in a Southern Chinese population. This
SNP was not included in our study, as it was unable to be
genotyped in a multiplex with the other SNPs. However, it is
in strong linkage disequilibrium with our two associated tag
SNPs (rs17576 and rs3918249, r2=0.85 and 0.86, respectively,
in the HapMap, CEU sample), suggesting a similar finding in
the current study. Further replications are required to directly
examine the association of rs2550889 SNP with PACG in
Australian individuals.
Interestingly, these three previous studies all in Asian
populations showed that the A/A genotype of SNP rs17576
was more common in PACG cases than in normal controls.
Thus, the minor A allele conferred risk for PACG. In the
current Caucasian study, we find that the A allele confers
protection against PACG and is the commoner allele in this
population. There is a well documented difference in allele
frequency across populations at this SNP. Asian populations
range from 0.22 to 0.30 [9-11,19,20], while the frequency in
Caucasians  is  approximately  0.65  [21-24].  This  is  also
observed in HapMap.
The opposite association of an allele or genotype of the
same SNP with disease could be due to different functional
effects among different ethnic groups, or the heterogeneous
effect of the same variant such as genetic background or
environmental factors [25]. This “flip-flop” association may
indicate that rs17576 is not the causative allele despite being
a  non-synonymous  change  (Gln279Arg),  but  that  the  risk
variants occur on different genetic backgrounds in different
ethnicities. Additionally, the fact that this variant is predicted
to be benign or tolerated by both PolyPhen and SIFT supports
this hypothesis. Examples of such “flip-flop” associations
have been previously reported [25], and are well established
in  ophthalmology  for  the  coding  lysyl  oxidase-like  1
(LOXL1) variant rs1048661 (R141L) SNP associated with
pseudo-exfoliation  syndrome  in  opposite  directions  in
Japanese  population  compared  with  Caucasians  [26].
Alternatively, the findings could represent type 1 errors that
do not replicate in further studies.
In Conclusion, our results show a significant association
between MMP9 polymorphisms and PACG in the Australian
Caucasian population, although the mechanism of MMP9 in
causing this blinding disease is undetermined. This is the first
study  to  suggest  an  association  between  MMP9
polymorphisms  and  PACG  in  the  Australian  Caucasian
population, and one of the first studies to investigate angle
closure  glaucoma  genetics  in  the  Caucasian  population.
Additional  replication  studies  in  populations  of  similar
ethnicity to the Australian Caucasian population are necessary
to confirm this association.
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